Treatment of gorham-stout disease with combination sirolimus and denosumab
Journal of the Endocrine Society. 2019;3(Supplement_1):MON-517.
Abstract
An abstract is not available in the lab archive. View the paper at its source.
This 2019 case report describes combination sirolimus and denosumab treatment for Gorham-Stout disease, followed by zoledronic acid. Imaging showed no further bone loss after an early new rib lesion; the authors note treatment-related adverse events and the need for further study.
Summary
The report describes a 44-year-old man diagnosed with Gorham-Stout disease after imaging showed an absent right scapula and rib lesions with fractures. Treatment consisted of two years of monthly denosumab and sirolimus, followed by three zoledronic acid infusions. Serial imaging identified one new rib lesion after six months of treatment but no subsequent bone loss. Reported adverse events included worsening hypertriglyceridemia, hypocalcemia, and hypophosphatemia. The authors emphasize that optimal treatment is not established and that further study and careful monitoring are needed. Read the article.
- Authors: Iris Hartley, Timothy McCarthy, Georgios Papadakis, Corina Millo, Ulas Bagci, Michael Collins, and Jenny Blau.
- Journal of the Endocrine Society. 2019;3(Supplement_1):MON-517.
- DOI: 10.1210/js.2019-MON-517.
Cite this work
Iris Hartley; Timothy McCarthy; Georgios Papadakis; Corina Millo; Ulas Bagci; Michael Collins; Jenny Blau (2019). Treatment of gorham-stout disease with combination sirolimus and denosumab. Journal of the Endocrine Society. 2019;3(Supplement_1):MON-517. https://doi.org/10.1210/js.2019-MON-517
BibTeX